# Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164

> **NCT00650104** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 76 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Ropinirole XL (formerly CR)

## Key facts

- **NCT ID:** NCT00650104
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2013-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00650104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00650104, "Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00650104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*